Induction of long-term peripheral microchimerism in non-human primates in a model of xenogeneic peripheral tolerance induction.
Xenotransplantation represents a promising solution to the ever increasing shortage of donor organs in allotransplantation. However, due to different and stronger modes of rejection, successful xenotransplantation will require different organ-protective regimes from those used in allogeneic transplantation today. Since one can not simply increase the dosage of the drugs used, immunomodulation or tolerance induction of the recipient would be the most desirable approach. Transfusion of donor leukocytes has been shown to downregulate recipient responses or even induce peripheral tolerance in small animal models. Since the infusion of donor cells represents a relatively simple approach, as one can purify and compose the inoculum exactly before infusion, we studied whether this approach can be successfully employed in a preclinical swine to non-human primate model of peripheral tolerance induction/immunomodulation. In our model, baboons underwent sequential column adsorption and complement blockade. The animals received only initial immunosuppression with cyclophosphamide. No further immunosuppression was given. Subsequently all animals received 1-3 x 10(10) porcine splenocytes i.v. Development and maintenance of chimerism was analyzed by sequential flow cytometric and PCR analyses. Other parameters studied included effects of the preparatory induction protocol. We could show that a low level of chimerism is maintained in these animals for up to 1.5 years, despite the fact that they received no additional immunosuppression after the initial one. At no time of the experiment did any animal display symptoms of poor health. Thus we demonstrate that the concept of donor leukocyte transfusion is transferable into preclinical xenotransplantation. We are currently conducting organ transplantation experiments into animals thus treated to directly analyze the immunomodulatory effect of the donor cells.
Simon
A R
AR
Dept. of Thoracic- and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany. simon@thg.mh-hannover.de
Schröder
C
C
Martin
U
U
Tessmann
R
R
Templin
C
C
Laaf
G
G
Wiebe
K
K
Steinhoff
G
G
Lapin
B
B
Chikobava
M
M
Haverich
A
A
D000818:Animals; D000910:Antibodies, Heterophile / Q000097:blood; D003520:Cyclophosphamide / Q000627:therapeutic use; D004187:Disaccharides / Q000276:immunology; D005112:Extracorporeal Circulation; D007108:Immune Tolerance / Q000276:immunology*; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney; D007962:Leukocytes / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D023421:Models, Animal; D010215:Papio; D010477:Perfusion; D013552:Swine; D018183:Transplantation Chimera / Q000276:immunology*; D014183:Transplantation, Heterologous / Q000502:physiology*
D000910:Antibodies, Heterophile; D004187:Disaccharides; D007166:Immunosuppressive Agents; C055075:galactosyl-(1-3)galactose; D003520:Cyclophosphamide